MDxHealth SA (NASDAQ:MDXH) Receives $7.75 Consensus Target Price from Analysts

Shares of MDxHealth SA (NASDAQ:MDXH) have received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $7.75.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th.

Hedge Funds Weigh In On MDxHealth

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDXH. GSA Capital Partners LLP purchased a new position in MDxHealth in the 3rd quarter valued at approximately $48,000. Jefferies Financial Group Inc. purchased a new position in MDxHealth in the 3rd quarter valued at approximately $53,000. Russell Investments Group Ltd. purchased a new position in MDxHealth in the 3rd quarter valued at approximately $461,000. Kennedy Capital Management LLC purchased a new position in MDxHealth in the 3rd quarter valued at approximately $1,826,000. Finally, FreeGulliver LLC raised its holdings in shares of MDxHealth by 104.7% in the 3rd quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after purchasing an additional 129,348 shares in the last quarter.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $1.95 on Thursday. The stock has a market capitalization of $96.53 million, a P/E ratio of -2.91 and a beta of 1.60. The company has a 50 day moving average price of $2.52 and a 200 day moving average price of $3.27. MDxHealth has a fifty-two week low of $1.70 and a fifty-two week high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $23.90 million for the quarter, compared to analysts’ expectations of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%. Research analysts forecast that MDxHealth will post -0.41 earnings per share for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.